Published in Clin Exp Immunol on September 01, 2009
Establishment of HIV-1 latency in resting CD4+ T cells depends on chemokine-induced changes in the actin cytoskeleton. Proc Natl Acad Sci U S A (2010) 2.07
Spinoculation triggers dynamic actin and cofilin activity that facilitates HIV-1 infection of transformed and resting CD4 T cells. J Virol (2011) 1.17
Early myeloid dendritic cell dysregulation is predictive of disease progression in simian immunodeficiency virus infection. PLoS Pathog (2010) 0.98
A dichotomy in cortical actin and chemotactic actin activity between human memory and naive T cells contributes to their differential susceptibility to HIV-1 infection. J Biol Chem (2012) 0.96
The trinity of the cortical actin in the initiation of HIV-1 infection. Retrovirology (2012) 0.95
Differential ligand-signaling network of CCL19/CCL21-CCR7 system. Database (Oxford) (2015) 0.81
Establishment and Reversal of HIV-1 Latency in Naive and Central Memory CD4+ T Cells In Vitro. J Virol (2016) 0.80
HIV persistence: chemokines and their signalling pathways. Cytokine Growth Factor Rev (2012) 0.80
Enhanced levels of CCL19 in patients with advanced acquired immune deficiency syndrome (AIDS). Clin Exp Immunol (2012) 0.79
Increased expression of the homeostatic chemokines CCL19 and CCL21 in clinical and experimental Rickettsia conorii infection. BMC Infect Dis (2014) 0.75
Cytokines Elevated in HIV Elite Controllers Reduce HIV Replication in vitro and Modulate HIV Restriction Factor Expression. J Virol (2017) 0.75
Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol (1999) 13.55
CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs. Cell (1999) 12.50
Chemokine: receptor structure, interactions, and antagonism. Annu Rev Immunol (2007) 3.43
Chemokines: multiple levels of leukocyte migration control. Trends Immunol (2004) 3.32
Selective CXCR4 antagonism by Tat: implications for in vivo expansion of coreceptor use by HIV-1. Proc Natl Acad Sci U S A (2000) 2.23
CCR7 ligands CCL19 and CCL21 increase permissiveness of resting memory CD4+ T cells to HIV-1 infection: a novel model of HIV-1 latency. Blood (2007) 2.21
Chronic innate immune activation as a cause of HIV-1 immunopathogenesis. Clin Immunol (2007) 2.19
The impact of CCR7 and CXCR5 on lymphoid organ development and systemic immunity. Immunol Rev (2003) 1.79
The chemokine CCL21 modulates lymphocyte recruitment and fibrosis in chronic hepatitis C. Gastroenterology (2003) 1.64
CCL19 and CCL21 induce a potent proinflammatory differentiation program in licensed dendritic cells. Immunity (2005) 1.63
Pulmonary expression of CXC chemokine ligand 13, CC chemokine ligand 19, and CC chemokine ligand 21 is essential for local immunity to influenza. Proc Natl Acad Sci U S A (2007) 1.56
Control of HIV-1 infection by soluble factors of the immune response. Nat Rev Microbiol (2004) 1.53
Enhanced expression of the homeostatic chemokines CCL19 and CCL21 in clinical and experimental atherosclerosis: possible pathogenic role in plaque destabilization. Arterioscler Thromb Vasc Biol (2006) 1.47
Simian immunodeficiency virus dramatically alters expression of homeostatic chemokines and dendritic cell markers during infection in vivo. Blood (2002) 1.35
HIV-1 Tat activates neuronal ryanodine receptors with rapid induction of the unfolded protein response and mitochondrial hyperpolarization. PLoS One (2008) 1.23
The lymphoid chemokine CCL21 costimulates naive T cell expansion and Th1 polarization of non-regulatory CD4+ T cells. Cell Immunol (2005) 1.13
Gene expression analysis of peripheral T cells in a subgroup of common variable immunodeficiency shows predominance of CCR7(-) effector-memory T cells. Clin Exp Immunol (2004) 0.93
Enhanced HIV-1 replication by chemokines constitutively expressed in secondary lymphoid tissues. Virology (1999) 0.90
HIV-1 Tat mediates degradation of RON receptor tyrosine kinase, a regulator of inflammation. J Immunol (2008) 0.85
Impaired CCR7 expression on plasmacytoid dendritic cells of HIV-infected children and adolescents with immunologic and virologic failure. J Acquir Immune Defic Syndr (2007) 0.84
Retention of phagocytic functions in cryopreserved human monocytes. J Leukoc Biol (1995) 0.83
Macrophage inflammatory protein-3 beta enhances IL-10 production by activated human peripheral blood monocytes and T cells. J Immunol (1999) 0.78
Hepatitis C infection in patients with primary hypogammaglobulinemia after treatment with contaminated immune globulin. N Engl J Med (1994) 3.73
Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: safety and costs. Lancet (1995) 2.43
High-intensity interval training improves peak oxygen uptake and muscular exercise capacity in heart transplant recipients. Am J Transplant (2012) 2.08
Quantification of the terminal complement complex in human plasma by an enzyme-linked immunosorbent assay based on monoclonal antibodies against a neoantigen of the complex. Scand J Immunol (1985) 2.06
Serum levels of tumor necrosis factor-alpha (TNF alpha) and soluble TNF receptors in human immunodeficiency virus type 1 infection--correlations to clinical, immunologic, and virologic parameters. J Infect Dis (1994) 1.93
Effect of high- versus low-dose angiotensin converting enzyme inhibition on cytokine levels in chronic heart failure. J Am Coll Cardiol (1999) 1.86
Elevated levels of serum-soluble CD14 in human immunodeficiency virus type 1 (HIV-1) infection: correlation to disease progression and clinical events. Blood (1998) 1.83
CXC-chemokines, a new group of cytokines in congestive heart failure--possible role of platelets and monocytes. Cardiovasc Res (2000) 1.74
Increased serum osteoprotegerin in disorders characterized by persistent immune activation or glucocorticoid excess--possible role in bone homeostasis. Eur J Endocrinol (2001) 1.71
Systemic inflammatory markers in COPD: results from the Bergen COPD Cohort Study. Eur Respir J (2009) 1.62
Decreased bone formative and enhanced resorptive markers in human immunodeficiency virus infection: indication of normalization of the bone-remodeling process during highly active antiretroviral therapy. J Clin Endocrinol Metab (1999) 1.61
Myocardial gene expression of leukaemia inhibitory factor, interleukin-6 and glycoprotein 130 in end-stage human heart failure. Eur J Clin Invest (2001) 1.55
IL-10 in HIV infection: increasing serum IL-10 levels with disease progression--down-regulatory effect of potent anti-retroviral therapy. Clin Exp Immunol (1999) 1.55
Clopidogrel increases expression of chemokines in peripheral blood mononuclear cells in patients with coronary artery disease: results of a double-blind placebo-controlled study. J Thromb Haemost (2006) 1.55
Myocardial expression of CC- and CXC-chemokines and their receptors in human end-stage heart failure. Cardiovasc Res (2000) 1.53
Osteoprotegerin concentrations and prognosis in acute ischaemic stroke. J Intern Med (2009) 1.53
Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. Circulation (1999) 1.53
Omega-3 fatty acids improve blood pressure control and preserve renal function in hypertensive heart transplant recipients. Eur Heart J (2001) 1.51
Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol (1999) 1.50
Favourable response to therapy with the anti-CD20 monoclonal antibody rituximab in primary chronic cold agglutinin disease. Br J Haematol (2001) 1.49
Primary immunodeficiency diseases in Norway. J Clin Immunol (2000) 1.48
Elevated plasma levels of reduced homocysteine in common variable immunodeficiency--a marker of enhanced oxidative stress. Eur J Clin Invest (1997) 1.48
Elevated circulating levels of C-C chemokines in patients with congestive heart failure. Circulation (1998) 1.46
Virtual histology assessment of cardiac allograft vasculopathy following introduction of everolimus--results of a multicenter trial. Am J Transplant (2012) 1.45
[Immunomodulating treatment in advanced heart failure--effect of intravenous immunoglobulin]. Tidsskr Nor Laegeforen (2001) 1.40
Synovectomy for haemophilic arthropathy: 6-21 years of follow-up in 16 patients. J Intern Med (1994) 1.40
[Natural products can be hazardous to health]. Tidsskr Nor Laegeforen (1992) 1.39
Enhanced activation of platelets with abnormal release of RANTES in human immunodeficiency virus type 1 infection. FASEB J (1998) 1.35
Subnormal serum concentration of 1,25-vitamin D in human immunodeficiency virus infection: correlation with degree of immune deficiency and survival. J Infect Dis (1994) 1.33
Interferons and interferon (IFN)-inducible protein 10 during highly active anti-retroviral therapy (HAART)-possible immunosuppressive role of IFN-alpha in HIV infection. Clin Exp Immunol (2000) 1.32
Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure. Circulation (2001) 1.29
Severe deficiency of 1,25-dihydroxyvitamin D3 in human immunodeficiency virus infection: association with immunological hyperactivity and only minor changes in calcium homeostasis. J Clin Endocrinol Metab (1998) 1.29
High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H. Blood (2001) 1.27
Interaction between chemokines and oxidative stress: possible pathogenic role in acute coronary syndromes. J Am Coll Cardiol (2001) 1.18
Release of cytokines, soluble cytokine receptors, and interleukin-1 receptor antagonist after intravenous immunoglobulin administration in vivo. Blood (1994) 1.12
Deficient lymphoid cell-mediated, PHA-induced cytotoxicity in rheumatoid arthritis patients. Scand J Immunol (1975) 1.10
Undercarboxylated matrix Gla protein is associated with indices of heart failure and mortality in symptomatic aortic stenosis. J Intern Med (2010) 1.08
Low numbers of regulatory T cells in common variable immunodeficiency: association with chronic inflammation in vivo. Clin Exp Immunol (2007) 1.08
Protein kinase A type I antagonist restores immune responses of T cells from HIV-infected patients. FASEB J (1998) 1.07
rFVIIa administered by continuous infusion during surgery in patients with severe congenital FVII deficiency. Haemophilia (2011) 1.07
Both IgA subclasses are reduced in parotid saliva from patients with AIDS. Clin Exp Immunol (1991) 1.05
Increased activation of protein kinase A type I contributes to the T cell deficiency in common variable immunodeficiency. J Immunol (1999) 1.05
The role of the tumor necrosis factor system and interleukin-10 during cytomegalovirus infection in renal transplant recipients. J Infect Dis (2000) 1.03
Effects of interferon-alpha on gene expression of chemokines and members of the tumour necrosis factor superfamily in HIV-infected patients. Clin Exp Immunol (2002) 1.03
Lifelong treatment with gammaglobulin for primary antibody deficiencies: the patients' experiences of subcutaneous self-infusions and home therapy. J Adv Nurs (1995) 1.02
Evidence for the involvement of galectin-3 in mesenchymal stem cell suppression of allogeneic T-cell proliferation. Scand J Immunol (2010) 1.02
Decreased vitamin A levels in common variable immunodeficiency: vitamin A supplementation in vivo enhances immunoglobulin production and downregulates inflammatory responses. Eur J Clin Invest (2000) 1.01
Effect of aerobic exercise training on plasma levels of tumor necrosis factor alpha in patients with heart failure. Am J Cardiol (2001) 1.01
Decreased serum lipocalin-2 levels in human immunodeficiency virus-infected patients: increase during highly active anti-retroviral therapy. Clin Exp Immunol (2008) 1.01
Complement activation in patients with congestive heart failure: effect of high-dose intravenous immunoglobulin treatment. Circulation (2001) 1.01
Enhanced interleukin-10 production in response to Mycobacterium avium products in mononuclear cells from patients with human immunodeficiency virus infection. J Infect Dis (1998) 1.00
Raised serum neopterin levels in patients with primary hypogammaglobulinaemia; correlation to other immunological parameters and to clinical and histological features. Clin Exp Immunol (1992) 1.00
Enhanced gene expression of chemokines and their corresponding receptors in mononuclear blood cells in chronic heart failure--modulatory effect of intravenous immunoglobulin. J Am Coll Cardiol (2001) 1.00
Acquired haemophilia: management of bleeds and immune therapy to eradicate autoantibodies. Haemophilia (2005) 0.99
Elevated serum levels of interleukin-4 and interleukin-6 in patients with common variable immunodeficiency (CVI) are associated with chronic immune activation and low numbers of CD4+ lymphocytes. Clin Immunol Immunopathol (1994) 0.98
Long-term outcome of chronic hepatitis C virus infection in primary hypogammaglobulinaemia. QJM (1999) 0.97
Reduction of leptin gene expression by dietary polyunsaturated fatty acids. J Lipid Res (2001) 0.97
Subclass composition and J-chain expression of the 'compensatory' gastrointestinal IgG cell population in selective IgA deficiency. Clin Exp Immunol (1992) 0.96
In vitro mitogen stimulation of synovial fluid lymphocytes from rheumatoid arthritis and juvenile rheumatoid arthritis patients: dissociation between the response to antigens and polyclonal mitogens. Scand J Immunol (1978) 0.96
Chemokines in myocardial failure -- pathogenic importance and potential therapeutic targets. Clin Exp Immunol (2001) 0.95
8-Iso-prostaglandin f(2alpha) reduces trophoblast invasion and matrix metalloproteinase activity. Hypertension (2000) 0.95
Levels of circulating adhesion molecules in congestive heart failure and after heart transplantation. Am J Cardiol (1998) 0.94
Circulating levels of RANTES in human immunodeficiency virus type 1 infection: effect of potent antiretroviral therapy. J Infect Dis (1998) 0.94
Inflammatory imbalance between IL-10 and TNFalpha in unstable angina potential plaque stabilizing effects of IL-10. Eur J Clin Invest (2002) 0.94
Virological and immunological effects of antioxidant treatment in patients with HIV infection. Eur J Clin Invest (2000) 0.94
Gene expression analysis of peripheral T cells in a subgroup of common variable immunodeficiency shows predominance of CCR7(-) effector-memory T cells. Clin Exp Immunol (2004) 0.93
Cytokine responses to fungal pathogens in Kupffer Cells are Toll-like receptor 4 independent and mediated by tyrosine kinases. Scand J Immunol (2005) 0.92
Impaired in vitro survival of monocytes from patients with HIV infection. Clin Exp Immunol (1990) 0.92
Common variable immunodeficiency and the complement system; low mannose-binding lectin levels are associated with bronchiectasis. Clin Exp Immunol (2005) 0.91